Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons
Abstract
Biologic therapies have become central to the long-term management of many chronic diseases, including inflammatory rheumatic diseases. Over recent years, the development and licensing pathways for biosimilars have become more standardized, and several biosimilars have been made available for patients with inflammatory rheumatic diseases, such as RA. Pre-licensing requirements for biosimilars mandate the demonstration of comparability with...
Paper Details
Title
Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons
Published Date
Aug 1, 2017
Journal
Volume
56
Issue
suppl_4
Pages
iv49 - iv62
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History